MarketPeel
Insider Trading Intelligence
AD

Andrea Difabio

XENE
CHIEF LEGAL OFFICER · XENON PHARMACEUTICALS INC. · CIK 0001692506
FILING MIX · LIFETIME71%/29%
BUYS
10
SELLS
4
TOTAL VALUE
$230.8K
COMPANIES
1
ACTIVE SINCE
Nov 2022
HOLDINGS NOW
7,301
AVG SELL PX
$58.45
TRADE KIND
SHOWING 14 / 14
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 6 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Andrea Difabio, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+100.00%-4.72%-1.51%-3.22%-3.22%
14d2+100.00%-6.64%-3.90%-2.74%-2.74%
30d2+50.00%+1.38%+2.00%-0.61%-0.61%
60d2+100.00%-3.65%+10.19%-13.84%-13.84%
90d2+100.00%-10.96%+9.21%-20.18%-20.18%
180d2(2 pending)
1y2(2 pending)
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
XENE · 7,301 shares · as of Mar 13, 2026
033,75067,500101,250135,0002023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 10 buys / 4 sellsCOVERAGE · 14 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
XENE
XENON PHARMACEUTICALS INC.
SALE10b5-1
10b5-1 plan
1,342$55.23$74.1K7,301Mar 13, 2026Mar 13, 2026View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASE
Chief Legal Officer
3,7508,643Mar 12, 2026Mar 13, 2026View →
XENE
XENON PHARMACEUTICALS INC.
SALE
Chief Legal Officer
3,75011,250Mar 12, 2026Mar 13, 2026View →
XENE
XENON PHARMACEUTICALS INC.
SALE10b5-1
10b5-1 plan
2,607$60.11$156.7K4,893Mar 10, 2026Mar 11, 2026View →
XENE
XENON PHARMACEUTICALS INC.
SALE
Chief Legal Officer
7,5000Mar 9, 2026Mar 11, 2026View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASE
Chief Legal Officer
7,5007,500Mar 9, 2026Mar 11, 2026View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
7,5007,500Mar 9, 2026Mar 11, 2026View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
15,00015,000Jan 9, 2026Jan 9, 2026View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
80,00080,000Jan 9, 2026Jan 9, 2026View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
15,00015,000Mar 12, 2025Mar 13, 2025View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
80,00080,000Mar 12, 2025Mar 13, 2025View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
100,000100,000Mar 11, 2024Mar 12, 2024View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
45,00045,000Mar 10, 2023Mar 14, 2023View →
XENE
XENON PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
135,000135,000Nov 7, 2022Nov 9, 2022View →
Other insiders · XENE
Loading peer insiders…
About this filer
CIK 0001692506
ROLE
Chief Legal Officer
PRIMARY
XENE
COMPANIES
1
ACTIVE SINCE
Nov 2022
MARKETPEEL · /INSIDER/0001692506DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback